Anti-CD38 mAbs represent a promising therapy for patients with multiple myeloma (MM) since CD38 is expressed at relatively low levels on myeloid and lymphoid cells, and at high levels in various malignant plasma cells, including MM. Here, CD38 is linked to plasma cell myeloma.